How the Sec20 protein affects nerve cells and may relate to ALS and frontotemporal dementia
Functional role of Sec20, a BH3 and Secretory (Sec) domain protein, in neurons and its relevance to a motor neuron disease in Drosophila
This project looks at whether changes in the Sec20 protein cause nerve cell damage through mitochondrial and recycling (autophagy) problems that link to adult-onset ALS and frontotemporal dementia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10829253 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are using fruit flies to see how Sec20 works in nerve cells and why losing it leads to motor problems and neuron loss. They will compare those effects to damage caused by the C9orf72 G4C2 repeat expansion, a common genetic cause of ALS-FTD, to see how the two interact. The team will study mitochondria, autophagy pathways, and neuronal survival using genetic and molecular experiments in the lab. Results will be used to connect fly findings to the human BNIP1/Sec20 pathway and help explain disease mechanisms.
Who could benefit from this research
Good fit: Adults with ALS or frontotemporal dementia, especially those known to carry the C9orf72 repeat expansion, would be most directly relevant to these findings.
Not a fit: People without ALS/FTD or whose disease is driven by unrelated causes are unlikely to see direct benefit from this laboratory research in the near term.
Why it matters
Potential benefit: If successful, this could reveal a new disease pathway and point to targets for therapies that protect motor neurons in ALS and FTD.
How similar studies have performed: Previous studies have linked mitochondrial and autophagy dysfunction and C9orf72 repeats to ALS/FTD, but the specific role of Sec20/BNIP1 in this pathway is a newer and less-tested area.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Bhat, Krishna Moorthi — University of Alabama at Birmingham
- Study coordinator: Bhat, Krishna Moorthi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.